Dr. Natasha Leighl’s Highlights in Lung Cancer, 2012, Parts

[NikoleV]

Dr. Natasha Leighl’s Highlights in Lung Cancer, 2012, Parts 1 and 2: New Options for Patients with EGFR Mutations, ALK and ROS1 Rearrangements

March 30th, 2013 - by Dr. Jack West

http://expertblog.lungevity.org/2013/03 ... t-1-and-2/

Click the link above to view the podcast links.

Here are the first two podcasts from Dr. Natasha Leighl’s webinar on “Highlights in Lung Cancer from 2012″. Dr. Leighl is a longtime friend who is a lung cancer expert at Princess Margaret Hospital in Toronto, Ontario, Canada. Earlier this year, she reviewed a wide range of topics that represented promising developments in lung cancer from 2012, some of which likely to lead to new treatment options for patients in the clinic over the next few years.

Her presentation opened with new information on potential treatment options for patients with advanced NSCLC that has an EGFR mutation. Here are the video and audio versions of the podcast, along with the figures for it.

Leighl HL in LC 2012 Pt 1 EGFR Mutn Pos Video Podcast

Leighl HL in LC 2012 Pt 1 EGFR Mutn Pos Audio Podcast

Leighl HL in LC 2012 Pt 1 EGFR Mutn Pos Figures

She continued her tour of lung cancer highlights with a discussion on XALKORI (crizotinib) for patients with either an ALK rearrangement or the newly identified ROS-1 rearrangement.

Here are the video and audio podcasts of the program, along with the figures for the program.

Leighl HL in LC 2012 Pt 2 ALK ROS Rearr NSCLC Video Podcast

Leighl HL in LC 2012 Pt 2 ALK ROS Rearr NSCLC Audio Podcast

Leighl HL in LC 2012 Pt 2 ALK ROS Rearr NSCLC Figs

We’ll have more of her presentation up here shortly, so please check back soon!